Report
BioNTech SE : FY review - Better 2021, initial 2022 guidance at this point in time looks good
>Strong 2021 on Comirnaty sales - FY 2021 sales came in at € 19bn, driven solely by commercial revenues related to its corona vaccine COMIRNATY, except for c. € 100m in R&D refunded revenues. This is in line with the consensus (FactSet) forecast of € 19bn, but above our forecast of € 16.9bn. As 2.6bn doses were shipped as part of the agreement with Pfizer and in its own territories in 2021 (we had 2.66bn in our model), we conclude that pricing was better than estimate...
Underlying
BioNTech SE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Martial Descoutures
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.